Pharmaceutical Sector Soars in India: A Look at Crocin API's 1.1 Lakh Crore Market Cap & 19.7-24% RO
As India's pharmaceutical sector makes waves in 2025, one company stands out for its remarkable growth trajectory, with a market cap of ₹1.1 lakh crore and ROE at an all-time high.
- Here are 22 clean bullet points summarizing the video:
- The pharmaceutical sector is making waves in India in 2025.
- The government is pushing India to become a pharmacy of the antique region.
- Many PLI skims have been introduced by the government for the pharma industry.
- B.L. Quit this Company was founded in 1995 by Rajiv Juneja, who dropped out of college at age 18.
- Initially, the company had a valuation of ₹50 lakh and has since grown to a market cap of around ₹1.1 lakh crore.
- API (Active Pharmaceutical Ingredients) is what actually causes the therapeutic effect.
- Examples of APIs include Crocin, Curcine, and Hedech.
- Short-term diseases are often treated with APIs.
- Companies like Mainkind Pharma invest heavily in research and development.
- The company's revenue has grown significantly from ₹22-23 to ₹24 (2023-2024).
- The company has a good market cap of around ₹1.1 lakh crore, making it a large-cap company.
- The ROE (Return on Equity) is 19.7%, and the ROCE (Return on Capital Employed) is 24%.
- The share holding pattern shows that promoter holdings are at 76.5%.
- The hope is that the promoter holding will not drop below 75%.
- There has been a recent acquisition in Q3 results.
- The speaker advises checking weather to weather and acting quickly, as the world is moving fast.
- A final goodbye is given with the phrase "Till Den Tech Care Jai Hind and Bye".
Source: CA Rachana Phadke Ranade via YouTube
❓ What do you think? What are the potential consequences of India's push to become a pharmacy hub for the Asian continent on the pharmaceutical sector as a whole? Feel free to share your thoughts in the comments!